European Biotech Stocks 2012/I
The EuroBiotech Stocks list offers a comparative tool for the performance of all listed European Biotech Stocks. To ease compatibility all quotes are converted to Euros. The performance is calculated over a period of 60 days before the effective date. Displayed highs and lows are taken from the last 52 weeks.
| Company | Perf. | Quote | H/L | |
| 1 | 4SC (D) | 94.8% | 2.63 | 4.4/1.3 |
| 2 | AB Science (F) | 16.9% | 6.08 | 11.4/4.8 |
| 3 | Abcam (UK) | -4.2% | 3.89 | 5.5/3.6 |
| 4 | Ablynx (B) | 21% | 2.93 | 9.3/2.5 |
| 5 | Actelion (CH) | 8.4% | 28.65 | 45.1/22.9 |
| 6 | Active Biotech (S) | 55.4% | 3.01 | 18.6/1.9 |
| 7 | Addex Pharma (CH) | 10.8% | 5 | 9.7/4.6 |
| 8 | Advanced Med. Sol. (UK) | 18.6% | 1 | 1.4/0.73 |
| 9 | Affitech (DK) | -22.7% | 0.02 | 0.07/0.02 |
| 10 | Agennix AG (D) | -2.7% | 2.82 | 4.2/2.4 |
| 11 | Algeta (N) | -9.7% | 19.52 | 28.4/13.5 |
| 12 | Almirall (E) | 6.7% | 5.37 | 9.1/4.6 |
| 13 | Analytik Jena (D) | 14.9% | 11.95 | 11.8/7.5 |
| 14 | Antisoma (UK) | 4.4% | 0.02 | 0.03/0.02 |
| 15 | Ark Therapeutics (UK) | -3.9% | 0.04 | 0.07/0.03 |
| 16 | Basilea (CH) | 25% | 31.7 | 63.6/23.2 |
| 17 | Bavarian Nordic (DK) | 45.6% | 7.11 | 36.4/4.9 |
| 18 | BB Biotech (CH) | 29.1% | 59.92 | 58.9/39 |
| 19 | BioAlliance (F) | 42.3% | 4.57 | 6.5/2.9 |
| 20 | Biofrontera (D) | -2.5% | 3.05 | 4.3/2 |
| 21 | Biotec Pharmacon (N) | 38% | 0.89 | 1.38/0.61 |
| 22 | Biotest VZ (D) | 6.1% | 39.7 | 51.8/35 |
| 23 | Biotie (FIN) | 0% | 0.8 | 0.8/0.34 |
| 24 | BTG (UK) | 12.4% | 3.88 | 4/2.4 |
| 25 | Cellectis (F) | 21.5% | 7.66 | 9.7/5.5 |
| 26 | Chronotech (S) | 0% | 0.02 | 0.06/0.04 |
| 27 | Clavis Pharma (N) | 44.8% | 8.23 | 8.8/3.6 |
| 28 | Cosmo (I) | 3.7% | 14.47 | 17.6/13 |
| 29 | Cytos (CH) | -1.6% | 1.43 | 12/1.3 |
| 30 | Deinove (F) | 31.6% | 8.52 | 21.7/5.1 |
| 31 | Devgen (B) | 7.9% | 5.18 | 7.2/3.7 |
| 32 | Diagenic (N) | -12.8% | 0.78 | 1.11/0.45 |
| 33 | DSM (NL) | 10.4% | 39.22 | 47.4/29.8 |
| 34 | Epigenomics (D) | -69.5% | 1.25 | 5/0.78 |
| 35 | Eurofins Scientific (F) | 0% | 61.47 | 76.9/46.6 |
| 36 | Evolva (CH) | -5.2% | 0.43 | 1.34/0.49 |
| 37 | Evotec (D) | 7.4% | 2.61 | 3.5/1.6 |
| 38 | ExonHit (F) | 62.6% | 1.48 | 2.87/0.94 |
| 39 | Fornix Bioscience (NL) | 6.6% | 0.64 | 3.45/0.53 |
| 40 | Galapagos (B) | 32% | 10.5 | 12.3/4.9 |
| 41 | Genfit (F) | 0% | 4.49 | 5.4/1.6 |
| 42 | Genmab (DK) | 70.7% | 6 | 8.6/3.4 |
| 43 | GW Pharmaceut. (UK) | 2.6% | 1.08 | 1.55/0.94 |
| 44 | HBM Bioventures (CH) | 2.9% | 33.04 | 41.9/32.1 |
| 45 | HybriGenics (F) | 27.7% | 1.38 | 2/1 |
| 46 | Intercell (A) | 33.5% | 2.35 | 10.4/1.7 |
| 47 | Ipsen (F) | 4.4% | 22.46 | 29/18.3 |
| 48 | Ipsogen (F) | 0% | 12.89 | 13.2/6.5 |
| 49 | Karolinska (S) | -2.9% | 2.58 | 4.8/2.3 |
| 50 | Lonza (CH) | -12% | 40.39 | 66.8/36 |
| 51 | LSP (NL) | 5.5% | 88.21 | 102/85.7 |
| 52 | Magforce (D) | -15.4% | 6.44 | 35.3/4.8 |
| 53 | MDX Health (B) | 13% | 1.65 | 2.6/1.3 |
| 54 | MediGene (D) | 27.3% | 1.35 | 2.85/0.81 |
| 55 | Metabolic Explorer (F) | 102.9% | 4.79 | 6.8/3.1 |
| 56 | MolMed (I) | 0% | 0.49 | 0.73/0.26 |
| 57 | Mologen (D) | 8.1% | 7.79 | 9/6.2 |
| 58 | MorphoSys (D) | 13.6% | 19.67 | 21.9/14.7 |
| 59 | Neovacs (F) | 11.1% | 3.8 | 5.3/2.7 |
| 60 | Newron (I) | 18.1% | 2 | 6.4/2 |
| 61 | Nicox (F) | 68.8% | 1.52 | 2.78/0.97 |
| 62 | Novagali (F) | 0% | 3.67 | 6.2/3.2 |
| 63 | Novozymes (DK) | -33% | 110.07 | 120.7/92.6 |
| 64 | Octoplus (NL) | 6.2% | 0.51 | 1.51/0.46 |
| 65 | Orexo (S) | -3.8% | 2.75 | 5.4/2.8 |
| 66 | Oxford Biomedica (UK) | -34.2% | 0.03 | 0.08/0.06 |
| 67 | Paion (D) | -17.6% | 0.7 | 2.4/1.3 |
| 68 | Pharming (NL) | -22.2% | 0.07 | 0.2/0.07 |
| 69 | Photocure (N) | 36.3% | 5.03 | 7/4.3 |
| 70 | Phytopharm (UK) | 32.2% | 0.1 | 0.12/0.07 |
| 71 | Plethora (UK) | 14.5% | 0.03 | 0.12/0.03 |
| 72 | Pronova (N) | -14% | 0.85 | 1.42/0.64 |
| 73 | Proximagen (UK) | 0% | 1.56 | 1.8/1.3 |
| 74 | Qiagen (D) | 13.7% | 12.48 | 15.3/9.1 |
| 75 | Renovo (UK) | 7.9% | 0.19 | 0.86/0.15 |
| 76 | Roche GS (CH) | 4.8% | 131.05 | 140.7/97.8 |
| 77 | Santhera (CH) | -7.6% | 3.82 | 7.4/3.9 |
| 78 | Sareum (UK) | -14.2% | 0.01 | 0.06/0 |
| 79 | Sartorius VZ (D) | 1.3% | 37.4 | 39.3/25.5 |
| 80 | Silence Therapeutics (UK) | 3.5% | 0.03 | 0.09/0.02 |
| 81 | Sygnis Pharma (D) | -71.9% | 0.59 | 3.3/1.2 |
| 82 | Syngenta (CH) | 4.6% | 226.34 | 263.7/171.6 |
| 83 | Thrombogenics (B) | -0.5% | 17.75 | 22.9/12.1 |
| 84 | Tigenix (F) | 2.9% | 0.7 | 1.5/0.57 |
| 85 | TopoTarget (DK) | 17.3% | 0.36 | 0.45/0.21 |
| 86 | Transgene (F) | 30.4% | 9.17 | 15.6/7.7 |
| 87 | UCB (B) | 1.8% | 31.09 | 34.1/25.6 |
| 88 | Vectura (UK) | .8% | 0.68 | 1.24/0.68 |
| 89 | Vernalis (UK) | 3.2% | 0.22 | 0.57/0.33 |
| 90 | Virbac (F) | -10.2% | 107 | 131.5/101.2 |
| 91 | Vita 34 (D) | -6% | 2.8 | 5.4/2.4 |
| 92 | Vivalis (F) | 27.9% | 6.27 | 8.2/5.5 |
| 93 | Wilex (D) | -8.2% | 3.45 | 5.5/3 |
| 94 | Zealand Pharma (DK) | 18.2% | 8.27 | 10.4/5.8 |
| 95 | Zeltia (E) | 31.7% | 1.99 | 3.1/1.4 |
Performance for 60 days, Highs and lows in 52 weeks.